Evaluating the Clinical Significance of Diazepam Binding Inhibitor in Alzheimer’s Disease: A Comparison with Inflammatory, Oxidative, and Neurodegenerative Biomarkers

Introduction: Alzheimer’s disease (AD) is one of the pathologies that the scientific world is still desperate for. The aim of this study was the investigation of diazepam binding inhibitor (DBI) as a prognostic factor for AD prognosis. Methods: A total of 120 participants were divided into 3 groups. Forty new diagnosed Alzheimer patients (NDG) who have been diagnosed but have not started AD treatment, 40 patients who diagnosed 5 years ago (D5YG), and 40 healthy control groups (CG) were included in the study. Levels of DBI, oxidative stress, inflammatory, and neurodegenerative biomarkers were compared between 3 groups. Results: Plasma levels of DBI, oligomeric Aβ, total tau, glial fibrillary acidic protein, α-synuclein, interleukin (IL) 1β, IL6, tumor necrosis factor α, oxidative stress index, high-sensitive C-reactive protein, and DNA damage were found higher in D5YG and NDG as compared to CG (p < 0.001). On the contrary, plasma levels of total thiol, native thiol, vitamin D and vitamin B12 were lower in D5YG and NDG as compared to CG (p < 0.001). Discussion: DBI may be a potential plasma biomarker and promising drug target for AD. It could help physicians make a comprehensive evaluation with cognitive and neurodegenerative tests.

[1]  K. Blennow,et al.  Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease , 2021, Brain : a journal of neurology.

[2]  Z. Bayraktaroglu,et al.  Left lateral parietal rTMS improves cognition and modulates resting brain connectivity in patients with Alzheimer’s disease: Possible role of BDNF and oxidative stress , 2021, Neurobiology of Learning and Memory.

[3]  P. Garzone,et al.  Alzheimer’s Disease and Other Dementias , 2020, Acupuncture for Brain.

[4]  I. Appollonio,et al.  Serum DBI and biomarkers of neuroinflammation in Alzheimer’s disease and delirium , 2020, Neurological Sciences.

[5]  F. Stanke-Labesque,et al.  Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment , 2020, Pharmacology & Therapeutics.

[6]  2020 Alzheimer's disease facts and figures , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[7]  B. Relja,et al.  Cytokines in Inflammatory Disease , 2019, International journal of molecular sciences.

[8]  M. O. Nava-Mesa,et al.  B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin , 2019, CNS neuroscience & therapeutics.

[9]  Zengai Chen,et al.  Aging Neurovascular Unit and Potential Role of DNA Damage and Repair in Combating Vascular and Neurodegenerative Disorders , 2019, Frontiers in Neuroscience.

[10]  M. Bektay,et al.  Investigation of the Effects of Biochemical Parameters on Alzheimer’s Disease , 2019, American journal of Alzheimer's disease and other dementias.

[11]  K. Blennow,et al.  Blood-based Biomarkers for Alzheimer ’ s Disease and Related Dementias Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer ’ s disease , 2019 .

[12]  H. Nielsen,et al.  α-synuclein in the pathophysiology of Alzheimer’s disease , 2019, Molecular Neurodegeneration.

[13]  Connor D. Courtney,et al.  Differential impacts on multiple forms of spatial and contextual memory in diazepam binding inhibitor knockout mice , 2019, Journal of neuroscience research.

[14]  Irving B. Weiner,et al.  Patients with Alzheimer’s Disease , 2019, Rorschach Assessment of Senior Adults.

[15]  D. Rujescu,et al.  Amyloid blood biomarker detects Alzheimer's disease , 2018, EMBO molecular medicine.

[16]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[17]  A. Koçyiğit,et al.  Curcumin induce DNA damage and apoptosis through generation of reactive oxygen species and reducing mitochondrial membrane potential in melanoma cancer cells. , 2017, Cellular and molecular biology.

[18]  Athanasios Alexiou,et al.  Biomarkers for Alzheimer’s Disease Diagnosis , 2017, Current Alzheimer research.

[19]  P. Calabresi,et al.  Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease , 2017, Scientific Reports.

[20]  C. Jack,et al.  Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort , 2016, Alzheimer's & Dementia.

[21]  Philip S. Insel,et al.  Plasma tau in Alzheimer disease , 2016, Neurology.

[22]  C. Jack,et al.  LEVELS OF TAU PROTEIN IN PLASMA ARE ASSOCIATED WITH NEURODEGENERATION AND COGNITIVE FUNCTION IN A POPULATION-BASED ELDERLY COHORT , 2016, Alzheimer's & Dementia.

[23]  K. Blennow,et al.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.

[24]  C. Annweiler,et al.  Vitamin D, Cognition and Alzheimer’s Disease: The Therapeutic Benefit is in the D-Tails , 2016, Journal of Alzheimer's disease : JAD.

[25]  S. Mahjoub,et al.  Altered plasma marker of oxidative DNA damage and total antioxidant capacity in patients with Alzheimer's disease , 2016, Caspian journal of internal medicine.

[26]  Xia Zhang,et al.  Role of oxidative stress in Alzheimer's disease , 2016, Biomedical reports.

[27]  H. Zetterberg.  Plasma amyloid β—quo vadis? , 2015, Neurobiology of Aging.

[28]  O. Erel,et al.  A novel and automated assay for thiol/disulphide homeostasis. , 2014, Clinical biochemistry.

[29]  P. Deyn,et al.  Increased CSF α-synuclein levels in Alzheimer's disease: Correlation with tau levels , 2014, Alzheimer's & Dementia.

[30]  T. Littlejohns,et al.  Vitamin D and the risk of dementia and Alzheimer disease , 2014, Neurology.

[31]  Michael W. Weiner,et al.  The future of blood-based biomarkers for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[32]  William T. Hu,et al.  Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease , 2013, Journal of the Neurological Sciences.

[33]  Henrik Zetterberg,et al.  Plasma tau levels in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[34]  M. D. Mayas,et al.  Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia , 2012, Experimental Gerontology.

[35]  C. A. Massaad.  Neuronal and Vascular Oxidative Stress in Alzheimer’s Disease , 2011, Current neuropharmacology.

[36]  Abderrahim Oulhaj,et al.  Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial , 2010, PloS one.

[37]  C. Annweiler,et al.  Vitamin D and cognitive performance in adults: a systematic review , 2009, European journal of neurology.

[38]  F. Coppedè,et al.  DNA damage and repair in Alzheimer's disease. , 2009, Current Alzheimer research.

[39]  J. Troncoso,et al.  Maximizing the Potential of Plasma Amyloid-Beta as a Diagnostic Biomarker for Alzheimer’s Disease , 2008, NeuroMolecular Medicine.

[40]  M. Mattson,et al.  Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment , 2007, Nucleic acids research.

[41]  R. Cacabelos,et al.  Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease , 2007, Neurobiology of Aging.

[42]  M. Penttonen,et al.  Diazepam binding inhibitor overexpression in mice causes hydrocephalus, decreases plasticity in excitatory synapses and impairs hippocampus-dependent learning , 2007, Molecular and Cellular Neuroscience.

[43]  O. Erel,et al.  A new automated colorimetric method for measuring total oxidant status. , 2005, Clinical biochemistry.

[44]  H. Vaudry,et al.  Beta‐amyloid peptides stimulate endozepine biosynthesis in cultured rat astrocytes , 2005, Journal of neurochemistry.

[45]  M A Lovell,et al.  Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease , 2005, Journal of neurochemistry.

[46]  O. Erel,et al.  A novel automated method to measure total antioxidant response against potent free radical reactions. , 2004, Clinical biochemistry.

[47]  R. Schmidt,et al.  Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging study , 2002, Annals of neurology.

[48]  Sudha Seshadri,et al.  Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease , 2002 .

[49]  G. Annoni,et al.  Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? , 2000, Journal of Neuroimmunology.

[50]  B. Bergamasco,et al.  Diazepam binding inhibitor-like immunoreactivity (DBI-LI) in human CSF Correlations with neurological disorders , 1988, Journal of the Neurological Sciences.

[51]  S. Paul,et al.  Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease. , 1986, Archives of general psychiatry.

[52]  Hyun Kim,et al.  Differences in C-reactive Protein Level in Patients with Alzheimers Disease andMild Cognitive Impairment , 2015 .

[53]  Liang Shen,et al.  Associations between Homocysteine, Folic Acid, Vitamin B12 and Alzheimer's Disease: Insights from Meta-Analyses. , 2015, Journal of Alzheimer's disease : JAD.

[54]  Neeraj Kumar,et al.  Neurological disorders. , 2015, World review of nutrition and dietetics.

[55]  C. Annweiler,et al.  Meta-analysis of memory and executive dysfunctions in relation to vitamin D. , 2013, Journal of Alzheimer's disease : JAD.

[56]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[57]  A. Guidotti,et al.  Diazepam binding inhibitor (DBI): a peptide with multiple biological actions. , 1991, Life sciences.

[58]  F. Buckley.  Christian , 1989, Horizons.